Assignee
KURA ONCOLOGY INC
US·33 granted patents·25 pending applications·111 citations·filing 2014–2025
Top patents by PatentIndex Score
58 records- 0196US11673898B2Substituted inhibitors of menin-MLL and methods of useKURA ONCOLOGY INC·Filed 2020·Granted Jun 13, 2023·6 cites·27 claims
- 0296US10781218B2Substituted inhibitors of menin-MLL and methods of useKURA ONCOLOGY INC·Filed 2017·Granted Sep 22, 2020·16 cites·20 claims
- 0396US10077271B2Methods and compositions for inhibiting the interaction of menin with MLL proteinsKURA ONCOLOGY INC·Filed 2017·Granted Sep 18, 2018·14 cites·18 claims
- 0494US9956215B1Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2017·Granted May 1, 2018·5 cites·30 claims
- 0593US10752639B2Bridged bicyclic inhibitors of menin-MLL and methods of useKURA ONCOLOGY INC·Filed 2017·Granted Aug 25, 2020·8 cites·14 claims
- 0692US12410184B2Crystalline forms of a menin inhibitorKURA ONCOLOGY INC·Filed 2024·Granted Sep 9, 2025·1 cites·35 claims
- 0792US10588907B2Methods and compositions for inhibiting the interaction of menin with MLL proteinsKURA ONCOLOGY INC·Filed 2016·Granted Mar 17, 2020·6 cites·1 claims
- 0892US10426767B2Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2018·Granted Oct 1, 2019·3 cites·34 claims
- 0992US10174041B2Methods and compositions for inhibiting the interaction of menin with MLL proteinsKURA ONCOLOGY INC·Filed 2018·Granted Jan 8, 2019·11 cites·24 claims
- 1092US9707221B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2016·Granted Jul 18, 2017·8 cites·23 claims
- 1189US10292979B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2018·Granted May 21, 2019·4 cites·28 claims
- 1289US10137121B2Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2017·Granted Nov 27, 2018·2 cites·30 claims
- 1388US11542248B2Methods and compositions for inhibiting the interaction of menin with MLL proteinsKURA ONCOLOGY INC·Filed 2018·Granted Jan 3, 2023·4 cites·14 claims
- 1488US10022364B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2017·Granted Jul 17, 2018·4 cites·14 claims
- 1587US11672774B2Methods of treating squamous cell carcinomas with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2021·Granted Jun 13, 2023·1 cites·50 claims
- 1687US11207314B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2018·Granted Dec 28, 2021·1 cites·17 claims
- 1787US10980793B2Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2019·Granted Apr 20, 2021·1 cites·30 claims
- 1887US9624228B2Inhibitors of ERK and methods of useKURA ONCOLOGY INC·Filed 2014·Granted Apr 18, 2017·3 cites·17 claims
- 1986US10335404B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2017·Granted Jul 2, 2019·3 cites·24 claims
- 2085US10471055B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2016·Granted Nov 12, 2019·3 cites·28 claims
- 2184US12018011B2Macrocyclic compounds and compositions, and methods of preparing and using the sameKURA ONCOLOGY INC·Filed 2023·Granted Jun 25, 2024·1 cites·222 claims
- 2284US11555041B2Bridged bicyclic inhibitors of menin-MLL and methods of useKURA ONCOLOGY INC·Filed 2020·Granted Jan 17, 2023·1 cites·10 claims
- 2382US2023089412A1Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 2481US11291663B2Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2018·Granted Apr 5, 2022·1 cites·21 claims
- 2581US10806730B2Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2017·Granted Oct 20, 2020·1 cites·26 claims
- 2678US11649251B2Substituted inhibitors of menin-MLL and methods of useKURA ONCOLOGY INC·Filed 2018·Granted May 16, 2023·1 cites·19 claims
- 2778US9951078B2Inhibitors of ERK and methods of useKURA ONCOLOGY INC·Filed 2017·Granted Apr 24, 2018·1 cites·29 claims
- 2876US11124839B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2017·Granted Sep 21, 2021·1 cites·34 claims
- 2976US2024358703A1Methods for treating hematological malignancies and ewing's sarcomaKURA ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 3073US12521396B2Pharmaceutical compositions comprising a MENIN inhibitorKURA ONCOLOGY INC·Filed 2024·Granted Jan 13, 2026·0 cites·28 claims
- 3172US11541045B2Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2018·Granted Jan 3, 2023·0 cites·39 claims
- 3272US2025361242A1Crystalline forms of a menin inhibitorKURA ONCOLOGY INC·Filed 2025·Application pending·0 cites
- 3370US12466835B1Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the sameKURA ONCOLOGY INC·Filed 2024·Granted Nov 11, 2025·0 cites·28 claims
- 3468US10301317B2Inhibitors of ERK and methods of useKURA ONCOLOGY INC·Filed 2018·Granted May 28, 2019·0 cites·34 claims
- 3568US2025304589A1Methods and compositions for inhibiting the interaction of menin with mll proteinsKURA ONCOLOGY INC·Filed 2025·Application pending·0 cites
- 3667US2019292194A1Inhibitors of erk and methods of useKURA ONCOLOGY INC·Filed 2019·Application pending·0 cites
- 3767US2025320225A1Substituted inhibitors of menin-mll and methods of useKURA ONCOLOGY INC·Filed 2025·Application pending·0 cites
- 3867US2024287023A1Macrocyclic compounds and compositions, and methods of preparing and using the sameKURA ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 3966US2025340566A1Bridged bicyclic inhibitors of menin-mll and methods of useKURA ONCOLOGY INC·Filed 2025·Application pending·0 cites
- 4065US2021381063A1Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 4165US2023248683A1Methods of treating squamous cell carcinomas with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 4264US2025255869A1Methods for treating hematological malignancies and ewing's sarcomaKURA ONCOLOGY INC·Filed 2025·Application pending·0 cites
- 4362US11944627B2Methods for treating hematological malignancies and Ewing's sarcomaKURA ONCOLOGY INC·Filed 2018·Granted Apr 2, 2024·0 cites·20 claims
- 4461US2025320229A1Substituted inhibitors of menin-mll and methods of useKURA ONCOLOGY INC·Filed 2025·Application pending·0 cites
- 4561US2025152591A1Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitorsKURA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 4656US2024024301A1Methods of treating head and neck squamous cell carcinomaKURA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 4754US2023095934A1Treatment of hematological malignancies with inhibitors of meninKURA ONCOLOGY INC·Filed 2019·Application pending·0 cites
- 4854US2022002396A1Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2019·Application pending·0 cites
- 4953US2022143006A1Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 5051US2022142983A1Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when KURA ONCOLOGY INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →